A newly identified chromosomal microdeletion of the rapsyn gene causes a congenital myasthenic syndrome
- PMID: 15482960
- DOI: 10.1016/j.nmd.2004.06.010
A newly identified chromosomal microdeletion of the rapsyn gene causes a congenital myasthenic syndrome
Abstract
The objective is mutation analysis of the RAPSN gene in a patient with sporadic congenital myasthenic syndrome (CMS). Mutations in various genes encoding proteins expressed at the neuromuscular junction may cause CMS. Most mutations affect the epsilon subunit gene of the acetylcholine receptor (AChR) leading to endplate AChR deficiency. Recently, mutations in the RAPSN gene have been identified in several CMS patients with AChR deficiency. In most patients, RAPSN N88K was identified, either homozygously or heteroallelic to a second missense mutation. A sporadic CMS patient from Germany was analyzed for RAPSN mutations by RFLP, long-range PCR and sequence analysis. Clinically, the patient presents with an early onset CMS, associated with arthrogryposis multiplex congenita, recurrent episodes of respiratory insufficiency provoked by infections, and a moderate general weakness, responsive to anticholinesterase treatment. The mutation RAPSN N88K was found heterozygously to a large deletion of about 4.5 kb disrupting the RAPSN gene. Interestingly, an Alu-mediated unequal homologous recombination may have caused the deletion. We hypothesize that numerous interspersed Alu elements may predispose the RAPSN locus for genetic rearrangements.
Similar articles
-
Impaired receptor clustering in congenital myasthenic syndrome with novel RAPSN mutations.Neurology. 2006 Oct 10;67(7):1159-64. doi: 10.1212/01.wnl.0000233837.79459.40. Epub 2006 Aug 23. Neurology. 2006. PMID: 16931511 Clinical Trial.
-
Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients.Neurology. 2003 Jun 10;60(11):1805-10. doi: 10.1212/01.wnl.0000072262.14931.80. Neurology. 2003. PMID: 12796535
-
Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine.Neuromuscul Disord. 2004 Mar;14(3):202-7. doi: 10.1016/j.nmd.2003.11.004. Neuromuscul Disord. 2004. PMID: 15036330
-
Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.Expert Rev Mol Med. 2007 Aug 9;9(22):1-20. doi: 10.1017/S1462399407000427. Expert Rev Mol Med. 2007. PMID: 17686188 Review.
-
Congenital myasthenic syndromes: progress over the past decade.Muscle Nerve. 2003 Jan;27(1):4-25. doi: 10.1002/mus.10269. Muscle Nerve. 2003. PMID: 12508290 Review.
Cited by
-
High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays.PLoS One. 2007 Sep 19;2(9):e918. doi: 10.1371/journal.pone.0000918. PLoS One. 2007. PMID: 17878953 Free PMC article.
-
Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients.Neurology. 2009 Jul 21;73(3):228-35. doi: 10.1212/WNL.0b013e3181ae7cbc. Neurology. 2009. PMID: 19620612 Free PMC article.
-
LRP4 is critical for neuromuscular junction maintenance.J Neurosci. 2014 Oct 15;34(42):13892-905. doi: 10.1523/JNEUROSCI.1733-14.2014. J Neurosci. 2014. PMID: 25319686 Free PMC article.
-
The role of Rapsyn in neuromuscular junction and congenital myasthenic syndrome.Biomol Biomed. 2023 Sep 4;23(5):772-784. doi: 10.17305/bb.2022.8641. Biomol Biomed. 2023. PMID: 36815443 Free PMC article. Review.
-
Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.Int J Mol Sci. 2023 Feb 13;24(4):3730. doi: 10.3390/ijms24043730. Int J Mol Sci. 2023. PMID: 36835142 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources